Laurus Labs Q1 FY27 Earnings Call: CDMO Revenue Surges 69% YoY, Capex Doubled to Rs. 2,000 Cr (LAURUSLABS)

Laurus Labs Ltd held its Q1 FY27 earnings call on July 24, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Record Revenue and Margin Expansion in Q1 FY26-27

• Revenue of Rs.2,026 crore — Q1 FY 2026-2027 total income from operations grew 29% YoY, driven by the CDMO and affordable medicines segments.
• EBITDA of Rs.644 crore — margin expanded 7 percentage points YoY to 31.8%, aided by capacity efficiency from late-stage and commercial projects.
• Profit after tax of Rs.368 crore — Q1 FY 2026-2027 PAT supported by operational leverage; ROCE came in at 19% versus 17.7% in FY 2025-2026.
• Gross margin of 62.7% — improved 3.3 percentage points YoY due to division mix and process improvements.
• Capex of Rs.394 crore — invested in Q1 FY 2026-2027; net debt stood at Rs.2,656 crore; Debt/EBITDA at 1.28x (vs 1.25x in Q4 FY 2025-2026).

CDMO Surges 69%, Blockbuster Molecule Exceeds Rs.200 Cr

• CDMO revenue of Rs.835 crore — small molecule CDMO grew 69% YoY in Q1 FY 2026-2027, driven by late-stage clinical and commercial deliveries; commercial supplies contributed 55% of CDMO revenue.
• At least one molecule generating ~Rs.200 crore+ — management confirmed the CDMO business includes a blockbuster molecule at this revenue level as of Q1 FY26-27, but declined granular product details due to confidentiality.
• Custom synthesis run rate of ±Rs.100 crore — management confirmed it is fair to assume this level can be maintained for at least Q2 and Q3 FY 2026-2027; commercial supplies share of custom synthesis rose to 55% in Q1.
• Arvinas Therapeutics agreement — the company signed a development and commercial agreement for two ADC molecules targeting the India market (clinical stage); a "big pharma client" was also onboarded.
• CDMO target of at least 50% of revenue by FY30 — management reaffirmed this goal despite analyst questions about postponement; CDMO exit rate in Q1 was ~Rs.820-800+ crore (~42% of total revenue).
• CDMO revenues entirely from innovator molecules — all CDMO revenues come from on-patent molecules; off-patent contract manufacturing is classified as CMO under affordable medicines; no single product or customer contributes significantly.

Capex Doubled to Rs.2,000 Cr, Three-Horizon Strategy

• Capex guidance raised to Rs.2,000 crore for FY26-27 — revised upward from Rs.1,500 crore (originally Rs.1,000 crore) within six months, driven by capacity needs for existing customers and expansion into advanced intermediates and new modalities.
• Incremental Rs.500 crore — supports multiple products and customers across human health and animal health portfolios (both API and intermediates, mostly API in CDMO); not tied to a single customer or product.
• Three-horizon capital allocation strategy — CFO V. V. Ravi Kumar stated that a decision was taken to allocate up to 10% of profits to disruptive technologies (in-house or external); capex in small molecule API and drug product is now "lumpy but predictable."
• Karka JV: Rs.400 crore invested, Rs.400 crore more required — the oncology facility will be ready early FY 2027-2028, and the solid oral facility will be ready in the second half of calendar year 2027; part of the additional investment will come from a loan from the partner.
• Precision fermentation (Laurus Bio) — Vizag 400+ KL commercial facility going operational in early FY 2027-2028; current revenue ~Rs.200 crore; management expects the next 12 to 18 months to be crucial for determining which molecules will scale.

Margin Expansion Underway, ROCE Trajectory Positive

• Gross margin improved to ~63% — from 61% in the prior period; management expects similar margins in coming quarters, citing some pressure from global conflicts but not significant.
• Asset turnover target >1.0x — management stated they are almost there; the analyst suggestion of 1.5x was not adopted. Long-term targets include 1.1x asset turnover and 25% ROCE (period unspecified).
• ROCE expected to reach ~19% in FY 2026-2027 — up from 17.7% in FY 2025-2026; heavy capex in FY 2026-2027 is expected to keep ROCE near 23% in the near term.
• Forex gain of Rs.5 crore — recorded in Q1 FY 2026-2027; 55-60% of consolidated revenue comes from direct exports, with the remainder in rupees.
• Operating cash flow not disclosed — management declined to provide Q1 FY 2026-2027 operating cash flow on the call, stating they would revert later.
• Constant currency revenue growth of ~2% — amounting to Rs.36 crore in Q1 FY 2026-2027; the low growth relative to ~30% INR depreciation is explained by the 55-60% export revenue mix.

R&D Spend Up 70%, ADC and Peptide Pipelines Advance

• R&D expenditure at 5.8% of revenue — Q1 FY 2026-2027 R&D spend increased ~70% YoY, driven by capability development for gene therapy, ADC technology, and complex pipeline building; management noted it is in line with the full-year target.
• Two preclinical ADC assets licensed from Arvix Therapeutics — the company completed in vitro proof of concept; expects to conduct GLP tox studies in India by mid-FY 2027-2028 and then start preclinical trials; ADC programs provide access to conjugation, purification, and fill-finish capabilities.
• Two in-licensed antibody programs at preclinical stage — management guided a development timeline of at least 3–4 years in India before potential revenue generation, pending GLP toxicity, IND filing, and Phase 1/2 trials.
• Peptide market growing at ~30%+ — management confirmed it is supporting multiple peptide classes beyond GLP-1; GLP-1 peptides (e.g., semaglutide) are expected to be a meaningful area for Laurus Labs, but no timeline or commercial qualification was confirmed.
• 5-year vision for future modalities — management described its vision as "investing in future modalities (cell & gene therapy, ADCs, peptides)" through technology absorption from partnerships (Arvix, ImmunoAct) and licenses (IIT Kanpur).
• SBTi validation of emission targets — the company's near-term emission reduction targets were validated by the Science Based Targets initiative (SBTi) in Q1 FY 2026-2027, supporting ESG commitments.

Affordable Medicines Up 10%, ARV Mix Shifts Lower

• Affordable medicines revenue of Rs.1,156 crore — up 10% YoY in Q1 FY 2026-2027, driven by higher volumes in ARVs and Onco, as well as sustained momentum from recently launched products in developed markets.
• ARV segment revenue of Rs.669 crore — comprised of Rs.415 crore API and Rs.254 crore FDF in Q1 FY 2026-2027; the ARV vs. non-ARV mix stood at approximately 1/3 ARV and 2/3 non-ARV, with management expecting the ARV share to decline further and not exceed this level.
• 92 cumulative DMF filings, 96 product filings — as of Q1 FY 2026-2027; the division filed two developed-market formulation dossiers during the quarter.
• New office in South Africa — established in Q1 FY 2026-2027 to capture regional growth opportunities; operational execution improved with gains in supply reliability, manufacturing efficiency, and supply-chain resilience.
• 24 quality audits passed — multiple regulators and customers conducted audits in Q1 FY 2026-2027, all successfully passed without any critical findings.
• 500+ acre land parcel from Andhra Pradesh government — final handover is in the final stages, supporting future capacity expansion.